Huntington's disease is caused by an expanded CAG repeat in the gene encoding huntingtin (HTT), resulting in loss of striatal and cortical neurons. Given that the gene product is widely expressed, it remains unclear why neurons are selectively targeted. Here we show the relationship between synaptic and extrasynaptic activity, inclusion formation of mutant huntingtin protein (mtHtt) and neuronal survival. Synaptic N-methyl-d-aspartatetype glutamate receptor (NMDAR) activity induces mtHtt inclusions via a T complex-1 (TCP-1) ring complex (TRiC)-dependent mechanism, rendering neurons more resistant to mtHtt-mediated cell death. In contrast, stimulation of extrasynaptic NMDARs increases the vulnerability of mtHtt-containing neurons to cell death by impairing the neuroprotective cyclic AMP response element-binding protein (CREB)-peroxisome proliferator-activated receptor- coactivator-1 (PGC-1) cascade and increasing the level of the small guanine nucleotide-binding protein Rhes, which is known to sumoylate and disaggregate mtHtt. Treatment of transgenic mice expressing a yeast artificial chromosome containing 128 CAG repeats (YAC128) with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs and ameliorates neuropathological and behavioral manifestations. By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic NMDAR activity, decreases neuronal inclusions and worsens these outcomes. Our findings offer a rational therapeutic approach for protecting susceptible neurons in Huntington's disease.
a r t i c l e s Huntington's disease is an inherited neurodegenerative disorder caused by an expansion of a polyglutamine repeat in the aminoterminal region of huntingtin 1 . Aggregation of mtHtt into insoluble macro inclusions and early selective cell death of striatal and cortical neurons are features of the disease 2 . Notably, most, if not all, neurodegenerative disorders, whether or not genetically inherited like Huntington's disease, manifest abnormal misfolded proteins 3 . Although it has been known for many years that excessive NMDAR activity can mimic Huntington's disease 4 and that such activity might contribute to disease pathogenesis [5] [6] [7] , it remains unknown whether normal synaptic activity influences inclusion formation and neuronal survival. Additionally, mechanistic details relating electrophysiological activity and molecular pathways to protein misfolding and aggregation in disorders such as Huntington's disease have been lacking. Moreover, a mechanism-based treatment has not yet proven successful in individuals with Huntington's disease.
RESULTS

NMDAR synaptic activity is needed for mtHtt inclusions
To investigate the relationship between synaptic activity, inclusion formation and neurotoxicity induced by mtHtt, we initially used a neuronal cell culture model of Huntington's disease in which we transiently transfected primary striatal or cortical neurons from rat with constructs encoding either full-length or N-terminal Htt with wild-type or expanded polyglutamine repeats. Neurons transfected with wild-type Htt (wtHtt) showed diffuse cytoplasmic expression of huntingtin by immunocytochemistry, whereas both intranuclear and cytoplasmic macroscopic inclusions were present in neurons and neuropil transfected with mtHtt. Strikingly, when we curtailed endogenous NMDAR activity in these cultures with the NMDAR antagonists d-(-)-2 amino-5-phosphonovaleric acid (d-APV), memantine or ifenprodil, we observed a significant (P < 0.01) decrease in the number of mtHtt-containing inclusions ( Fig. 1a,b for cortical neurons and Supplementary Fig. 1a,b Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin 1 4 0 8 volume 15 | number 12 | december 2009 nature medicine a r t i c l e s for striatal neurons). In contrast, the α-amino-3-hydroxy-5-methyl-4-isooxazole propionic acid (AMPA)-sensitive glutamate receptor antagonist, 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX), did not affect inclusion formation (Fig. 1a,b and Supplementary Fig. 1a,b) . Moreover, neither CNQX nor NMDAR antagonists had any effect on normal huntingtin expression in transfected neurons ( Supplementary  Fig. 2) . Hence, the suppressive effect of NMDAR antagonists on mtHtt inclusion formation could not be attributed to a global suppression of protein expression. Notably, memantine decreased the percentage of neurons containing mtHtt inclusions only at high (30 µM) concentrations, but not at lower (≤10 µM) concentrations (Fig. 1a,b and Supplementary Fig. 1a,b) . To mimic more closely the pathophysiological situation, we next used neurons transfected with full-length mtHtt bearing a 44Q expansion (that is, expressing 44 consecutive glutamine residues), or neurons from the striatum of the transgenic YAC128 Huntington's disease mouse, which has a yeast artificial chromosome (YAC) encoding the entire human huntingtin gene (HTT) containing 128 CAG repeats 8 . These models produced similar findings ( Supplementary Figs. 3 and 4) .
We have shown that, unlike other NMDAR antagonists, such as ifenprodil and d-APV, memantine is an open-channel blocker, acting predominantly via a mechanism characterized by uncompetitive inhibition with a fast 'off-rate' (designated UFO drug action); through this mechanism low micromolar concentrations of the drug preferentially inhibit excessive, primarily extrasynaptic, stimulation of NMDARs but relatively preserve physiological synaptic transmission 9, 10 . In contrast, higher concentrations of memantine lose this selectivity and also inhibit normal NMDAR-mediated synaptic activity like other NMDAR antagonists. Thus, blockade of inclusion formation by memantine at higher concentrations, but not lower concentrations, most likely results from interrupting endogenous synaptic activity in these cultures. To further characterize the role of synaptic activity in mtHtt aggregation, we used two additional pharmacological tools to suppress normal excitatory synaptic transmission. Both tetrodotoxin (to block Na + channels and thus the propagation of action potentials that lead to endogenous synaptic activity) and NO-711 (to block GABA uptake and hence augment inhibitory neurotransmission) decreased the percentage of neurons containing mtHtt inclusions ( Fig. 1c) . Taken together, our data suggest that interruption of normal excitatory synaptic activity (mediated by NMDARs) ameliorates macroinclusion formation.
Electrophysiological validation of pharmacological agents
To confirm the notion that our pharmacological manipulations modified synaptic activity, we used whole-cell recording with patch electrodes to study spontaneous excitatory postsynaptic currents (sEPSCs). We designed these experiments to analyze the effect of shortterm additions of drugs to determine their mechanism of action. We used the same drugs to prevent sEPSCs from triggering the intracellular signaling cascades involved in inclusion formation or neuronal cell death ( Fig. 1 and Supplementary Fig. 1 ). We found that total charge transfer during the NMDAR-mediated component of sEPSCs was significantly reduced by tetrodotoxin or NO-711 in both wtHtt-and mtHtt-transfected cortical neurons ( Fig. 2a,b) . Similarly, treatment with a high (30 µM) memantine concentration significantly inhibited the NMDAR-mediated component of sEPSCs, whereas a low (1-10 µM) memantine concentration relatively spared this synaptic activity ( Fig. 2c) . In contrast, ifenprodil (10 µM) blocked this synaptic activity ( Fig. 2d) . However, in the presence of 10 µM CNQX, NMDAR-mediated synaptic activity was not significantly attenuated ( Fig. 2e) .
Additionally, both memantine (even at low concentrations) and ifenprodil attenuated extrasynaptic NMDAR-mediated currents ( Fig. 2f) . We further confirmed the effect of low-dose memantine on extrasynaptic NMDAR-mediated currents by isolating extrasynaptic NMDAR activity using the previously published MK-801 protocol 11 (Supplementary Fig. 5 ). These electrophysiological findings validate the specificity of our pharmacological tools for NMDARs when studying mtHtt aggregation and neuronal cell death. Next, we examined whether NMDAR-sEPSCs were affected by mtHtt under our conditions. We found that total charge transfer during sEPSCs was not significantly different in mtHtt-versus wtHtt-transfected neurons ( Fig. 2g ). Similar findings have been observed in striatal slice recordings from a transgenic mouse model of Huntington's disease during low-frequency cortical afferent stimulation 12 , simulating the spontaneous activity level in our cultures. At higher levels of stimulation, mtHtt itself is known to enhance NMDAR activity 6 .
TRiC facilitates synaptic activity-dependent inclusion formation
Next, we investigated the molecular mechanism of mtHtt-induced inclusion formation. Recently, three groups reported in yeast and cell lines that the chaperonin TRiC (T complex-1 (TCP-1) ring complex) a r t i c l e s detoxifies mtHtt, at least in part by forming multiple mtHtt inclusions while decreasing toxic soluble microaggregates of mtHtt and thereby decreasing toxicity 13 . In neurons with preserved synaptic activity, we observed multiple, small mtHtt-containing inclusions ( Fig. 1a and Supplementary Figs. 1a and 3) , reminiscent of previous findings obtained after augmentation of TRiC activity. 14 Hence, we examined whether synaptic activity regulates the expression of TCP-1, the subunit of TRiC that preferentially interacts with mtHtt 14 . We added tetrodotoxin to our neuronal cultures to block synaptic activity and found that it significantly (P ≤ 0.001) decreased the expression of TCP-1 ( Fig. 3a) . Whereas lowdose memantine (10 µM) did not affect the TCP-1 expression, both high-dose memantine (30 µM) and ifenprodil also lowered TCP-1 protein levels ( Supplementary Fig. 6 ), supporting the notion that synaptic NMDAR activity is necessary for TCP-1 expression. To test whether TCP-1 is involved in synaptic activity-induced inclusion formation, we generated two shRNA interference constructs (shRNAs designated TCP-1 RNAi-1 and RNAi-2) to knock down TCP-1 expression. TCP-1 RNAi-1 and RNAi-2 reduced TCP-1 protein levels to 70% and 60%, respectively ( Supplementary Fig. 7 ). Both shRNA TCP-1 RNAi vectors significantly decreased inclusion formation from mtHtt ( Fig. 3b) . Additionally, knockdown of TCP-1 by RNAi occluded the inhibitory effect on inclusion formation exerted by suppression of synaptic activity with high-dose (30 µM) memantine ( Supplementary Fig. 8 ). Taken together, our results indicate that synaptic activity induces expression of TCP-1, which, in turn, mediates inclusion formation in neurons. Moreover, TRiC has been reported to cooperate with the heat shock protein-70 (Hsp70) chaperone system [15] [16] [17] ; Hsp70 attaches to mtHtt inclusions to protect cells from death 17, 18 . Indeed, here we observed localization of inclusions together with Hsp70 ( Supplementary Fig. 9 ), suggesting that the TRiC-Hsp70 system might ameliorate mtHtt toxicity.
Vulnerability of mtHtt + neurons via extrasynaptic NMDARs
We have shown that physiological synaptic NMDAR activity is necessary for macroinclusion formation in mtHtt-expressing (mtHtt + ) neurons. However, the relationship between mtHtt-induced inclusion formation and neurotoxicity in Huntington's disease pathogenesis has remained contentious 19, 20 . Large aggregates of abnormally folded proteins have been hypothesized to contribute to synaptic damage in neurodegenerative disorders 21 , but a recent report suggests that inclusion formation protects neurons from cell death 22 , possibly by decreasing the amount of toxic soluble forms of mtHtt 23 . Neurodegeneration in Huntington's disease has also been proposed to represent excitotoxic-mediated apoptotic cell death triggered by excessive activation of NMDARs 24 . Increased sensitivity to NMDARmediated excitotoxicity has been observed in the YAC128 mouse model of Huntington's disease 6 . In contrast, recent studies have indicated that physiological levels of synaptic NMDAR activity (predominantly composed of NR2A subunits in mature neurons) promote survival in the face of various forms of stress 11 . To our knowledge, the exact role of normal neuronal electrical activity in the pathogenesis of Huntington's disease has not previously been studied.
Our observation that endogenous synaptic NMDAR activity promotes formation of mtHtt-containing inclusions prompted our investigation of whether this normal activity could protect neurons. Conversely, we hypothesized that excessive activation of extrasynaptic NMDARs may increase neuronal vulnerability induced by mtHtt. To test this notion, we initially applied a relatively low concentration of exogenous glutamate (50 µM), which by itself was not excitotoxic to untransfected or wtHtt-transfected neurons under these conditions, to stimulate both extrasynaptic and synaptic receptors. Although transfection of mtHtt by itself did not result in neuronal death, as shown previously 6 , we found a r t i c l e s that mtHtt-expressing neurons became more vulnerable in the presence of 50 µM glutamate ( Fig. 4a) . When we treated mtHtt + neurons with memantine or ifenprodil, neuronal cell death induced by exogenous glutamate was significantly reduced (Fig. 4b,c ). Of note, we found that low concentrations of memantine (5-10 µM), which selectively block excessive extrasynaptic NMDAR activity while relatively sparing physiological synaptic NMDARs ( Fig. 2 and Supplementary Figs. 5 and 10) 9,10 , were sufficient to protect mtHtt-transfected neurons from glutamate challenge (Fig. 4b,c) . Additionally, extrasynaptic NMDARs preferentially contain NR2B subunits 25 , and ifenprodil, a relatively selective inhibitor of NR2B, blocked this neurotoxicity (Fig. 4b,c ) 6, 11 . Taken together, these results imply that mtHtt renders neurons more vulnerable to acute excitotoxic insults and that blockade of extrasynaptic NMDARs efficiently ameliorates this excitotoxic cell death. Note that we observed similar results for both truncated (N-terminal fragment) ( Fig. 4b) and full-length mtHtt-transfected constructs (Fig. 4c) .
Synaptic activity protects mtHtt + neurons from cell death
Next, we examined the effect of physiological synaptic activity on survival of neurons expressing mtHtt. We found that tetrodotoxin, which suppresses normal excitatory synaptic transmission, or NO-711, which enhances inhibitory neurotransmission, triggered significant cell death in mtHtt-expressing but not wtHtt-expressing neurons ( Fig. 4d and Supplementary Fig. 11 ). We then asked whether extrasynaptic NMDAR activity causes cell death in mtHtt + neurons when protective (physiological) synaptic NMDAR activity is inhibited. Accordingly, we investigated whether an NMDAR antagonist that preferentially blocks extrasynaptic activity could protect mtHtt a r t i c l e s neurons from toxicity induced by tetrodotoxin or NO-711. We found that treating mtHtt-transfected cultures with low concentrations (~5 µM) of memantine significantly reduced neuronal death induced by tetrodotoxin or NO-711 ( Fig. 4d) .
As synaptic neurotransmitter release is inhibited in the presence of neuronal activity blockade with tetrodotoxin, we questioned where the extrasynaptic glutamate originated in our culture system. Because the intracellular pool of glutamate, used for metabolic purposes, may be substantial, up to 10 mM per cell 26 , mtHtt-insulted neurons may leak glutamate from nonsynaptic sites. Additionally, similar to the intact brain, our culture system contains nonneuronal cells, predominantly astrocytes. Even in the absence of synaptic activity, glutamate released from astrocytes can activate extrasynaptic NMDARs in neurodegenerative conditions 27, 28 .
Neuronal electrical activity affects molecular pathways
We next wanted to investigate the relationship between electrical activity and the molecular pathways regulating macroinclusion formation and neuronal survival. Because we had found earlier that TCP-1 mediates inclusion formation (Fig. 3b) , we examined whether TCP-1 is involved in the survival of neurons expressing mtHtt. We found that knockdown of TCP-1 not only decreased inclusion formation but also significantly increased neuronal cell death in mtHttexpressing neurons (Fig. 4e) . These RNAi experiments imply a direct causal relationship between TCP-1 levels and consequent inclusion formation and neuronal cell death. Notably, this form of cell death was significantly ameliorated by blockade of extrasynaptic NMDARs with low-dose memantine (Fig. 4e) . Taken together, our results suggest that synaptic activity induces expression of TCP-1, which, in turn, contributes to protective inclusion formation and decreased neurotoxicity. Conversely, blockade of synaptic activity reduces TCP-1 levels, which, in turn, decreases mtHtt inclusion formation and contributes to neuronal cell death in conjunction with excessive extrasynaptic NMDAR activity.
Additionally, using low-dose memantine, we determined whether the level of Rhes, a small guanine nucleotide-binding protein recently reported to mediate mtHtt sumoylation, disaggregation and cytotoxicity 29 , is affected by blockade of extrasynaptic NMDARs. We found that low-dose memantine (5-10 µM) reduced Rhes protein expression ( Supplementary Fig. 12) , consistent with the notion that extrasynaptic NMDAR activity controls Rhes expression. Thus, the detrimental effects of excessive extrasynaptic NMDAR activity in the context of mtHtt may be ascribed, at least in part, to a relative increase in Rhes.
NMDARs modulate the CREB-PGC-1 pathway
CREB in concert with CREB-binding protein (CBP), which binds to phosphorylated CREB, triggers transcriptional events that upregulate the neuroprotective PGC-1α pathway; CREB/CBP activation has been shown to be decreased by extrasynaptic NMDAR activity 11 as well as by binding to soluble mtHtt 30 . We therefore hypothesized that impairment of the CREB-PGC-1α cascade may contribute to neuronal cell death in Huntington's disease 31 . Hence, we sought to determine whether CREB function is compromised in mtHtt-expressing neurons when synaptic activity is blocked. In mtHtt-transfected but not wtHtt-transfected neurons we found significantly lower CREB activity in the presence of tetrodotoxin, which suppresses excitatory synaptic activity (Fig. 4f) . Additionally, blockade of extrasynaptic NMDARs with low concentrations of memantine restored CREB function ( Fig. 4f ), suggesting that mtHtt and activation of extrasynaptic NMDARs are necessary for CREB inactivation.
We next determined the level of PGC-1α under these same conditions. We observed a significant decrease in PGC-1α abundance in mtHtt-transfected neurons in the presence of tetrodotoxin but preservation of PGC-1α protein in the presence of low concentrations of memantine ( Fig. 4g and Supplementary Fig. 13 ). Additionally, we found that RNAi-mediated knockdown of TCP-1 decreased CREB activity and PGC-1α protein levels in mtHtt-expressing neurons (Supplementary Fig. 14) . These findings support the notion that mtHtt in the absence of TCP-1, in conjunction with excessive extrasynaptic NMDAR activity, interferes with the neuroprotective CREB-PGC-1α cascade. Notably, decreased levels of PGC-1α probably contribute to cell death in mtHtt-transfected neurons exposed to tetrodotoxin (and thus in neurons with blocked synaptic activity lacking mtHtt inclusions). As would be predicted, cell death under these conditions was diminished by co-transfection with PGC-1α ( Fig. 4d) .
NMDAR activity modulates toxicity and behavior in YAC128 mice
The above findings raise the possibility that long-term blockade of extrasynaptic activity would be advantageous, whereas simultaneous blockade of synaptic activity might prove deleterious in vivo, for example, in the transgenic YAC128 Huntington's disease model mouse 8 (Supplementary Fig. 4b ). We hypothesized that the balance between synaptic and extrasynaptic activity in the face of mtHtt would determine neuronal survival. Therefore, whereas short-term blockade of both synaptic and extrasynaptic activity might cause transient improvement (as observed in the aforementioned experiments in culture), In contrast, maintenance of synaptic activity with abrogation of excessive extrasynaptic activity would be most beneficial to combat the deleterious effects of mtHtt. To test this hypothesis in vivo, we treated YAC128 mice in their drinking water with low-dose memantine (1 mg per kg body weight) to block extrasynaptic NMDAR activity or high-dose memantine (30 mg per kg body weight) to additionally block synaptic NMDAR activity, as we knew that these doses would produce low and high concentrations of memantine approaching those used in the culture experiments (see "Drug treatment" section in Supplementary Methods) 9, 10, [32] [33] [34] . We began treatment at 2 months of age and continued for 10 months until 12 months of age. We first analyzed mtHtt inclusions using immunostaining with antibody EM48, which recognizes N-terminal huntingtin and is highly specific for aggregates 35 . Treatment with low-dose memantine increased inclusion formation (Fig. 5a,b) , as confirmed by a filter trap assay ( Supplementary  Fig. 15 ), whereas high-dose memantine significantly decreased inclusion formation in 12-month-old YAC128 mice (Fig. 5a,b) . Accordingly, high-dose memantine also increased the amount of soluble mtHtt (Supplementary Fig. 16 ). These effects of memantine treatment on inclusion formation were not due to alterations in mtHtt protein expression, as low and high doses of memantine did not affect mtHtt abundance (Supplementary Fig. 17) . In contrast, TCP-1 protein levels increased with low-dose memantine and decreased with high-dose memantine (Supplementary Fig. 18 ), supporting the notion that normal synaptic NMDAR activity increases TCP-1 abundance and promotes inclusion formation. Next, we measured loss in striatal volume, a cardinal neuropathological feature of Huntington's disease 36 , in YAC128 mice. Low-dose memantine improved striatal volume, whereas high-dose memantine worsened this parameter (Fig. 5c) . These findings support our hypothesis that maintenance of synaptic activity, while inhibiting excessive extrasynaptic activity, is protective, and long-term blockade of synaptic activity is detrimental. We also monitored motor function by rotatrod testing at 12 months of age. YAC128 mice treated with low-dose memantine showed improvements on these motor tests, whereas high-dose-treated mice showed no improvement (Fig. 5d) . Taken together, these results support the premise that maintenance of synaptic activity with abrogation of extrasynaptic activity is beneficial in the YAC128 transgenic mouse model of Huntington's disease.
DISCUSSION
Our results provide a mechanistic framework to help understand the selective vulnerability of striatal and cortical neurons in Huntington's disease. We show here that synaptic activity controls expression of the chaperonin TRiC, which, in turn, modulates inclusion formation and the toxicity of mtHtt. Moreover, the electrical properties of these neurons coupled with the predominant effect of the small guanine nucleotidebinding protein Rhes and the CREB-PGC-1α pathway in this cell type 29, 37 renders them particularly sensitive to the toxic effects of mtHtt. Specifically, excessive extrasynaptic activity increases the relative amount of Rhes and, in conjunction with mtHtt, decreases CREB-PGC-1α activity to promote neuronal cell death. Coupled with a decrease in synaptic transmission, which also contributes to a decrease in CREB activity in the presence of mtHtt, neurons become increasingly vulnerable to injury and death (Fig. 6) . We speculate that these findings imply that therapies for Huntington's disease that minimize excessive extrasynaptic activity while maintaining or enhancing normal synaptic activity will yield considerable benefit. Notably, it has been contentious whether mtHtt inclusions are cytotoxic. The presence of inclusions may reflect either successful sequestration of toxic soluble oligomers of mtHtt and thus contribute to neuroprotection, or insufficient sequestration of toxic soluble mtHtt, which can no longer be accommodated by the inclusion formation process, and is thus toxic. Here we report that synaptic activity-driven inclusions are neuroprotective, supporting the former premise.
Nonetheless, we also show that cultured neurons containing mtHtt inclusions become increasingly vulnerable to excitotoxic insults, consistent with the notion that, over time, accumulation of excitotoxic challenges may eventually contribute to the death of mtHtt-expressing neurons in Huntington's disease 6 . We show not only that mtHtt increases the vulnerability of neurons to relatively low concentrations of exogenous glutamate but also that suppressing spontaneous excitatory synaptic activity can mimic this phenomenon via the excitotoxic effect of endogenous glutamate apparently acting on extrasynaptic receptors.
Our data in primary neurons manifesting synaptic activity may also explain why others have reported direct mtHtt toxicity in the absence of excitotoxic insult in yeast, various cell lines and synaptically immature neurons 14, 16, 17, 20, 30 . That is, the presence of normal synaptic activity in our mature neuronal cultures leads to the formation of inclusions, thereby avoiding toxic oligomers of mtHtt, whereas these other cell types lack synaptic activity and therefore are exposed to soluble mtHtt oligomers.
Our findings further suggest that the balance between synaptic and extrasynaptic NMDAR activity may be crucial in determining neuronal cell survival in Huntington's disease. We show that low concentrations of the NMDAR antagonist, memantine, afford the advantage of restoring excitatory balance by maintaining physiological synaptic activity while blocking excessive extrasynaptic NMDAR stimulation 9, 10 . Inhibiting excessive extrasynaptic NMDAR activity decreased Rhes protein levels, thus preserving mtHtt inclusions and lessening mtHtt a r t i c l e s cytotoxicity 29 . To the contrary, blocking synaptic activity with highdose memantine decreased the formation of inclusions and increased the amount of soluble mtHtt. Soluble mtHtt interferes with the neuroprotective CREB-PGC-1α pathway, thus accelerating neuronal cell death. Indeed, prolonged administration of high-dose memantine may contribute to toxicity for several reasons, including interference with other neuroprotective pathways that are dependent on synaptic activity, such as the phosphatidylinositol-3 kinase (PI3K)-Akt cascade 38, 39 . Thus, we posit that restoring excitatory balance, which is disrupted by mtHtt protein, can affect protein misfolding and protect neurons in Huntington's disease, as also suggested in a small, open-label human clinical trial of memantine in subjects with Huntington's disease 40 . This unique concept of balancing synaptic and extrasynaptic neuronal NMDAR activity may also lead to strategies to combat cell injury and death associated with other neurodegenerative disorders.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
ONLINE METHODS
Cell culture and transfection. We made primary cerebrocortical or striatal cultures, containing both neurons and glia, from embryonic day 16 Sprague-Dawley rat pups (Harlan) and grew them on 12-mm glass coverslips, as we have previously described 41 . All experiments involving primary cultures were performed with the approval of the Animal Care and Use Committee at Burnham Institute for Medical Research. We transfected cells via LipofectAMINE 2000 (Invitrogen) on the fifteenth to twentieth days in vitro with either N-terminal fragments of Htt consisting of exon 1 (Myc-wtHtt-N63-18Q or Myc-mtHtt-N63-148Q, provided by C.A. Ross (Johns Hopkins University School of Medicine)) or with full-length Htt (wtHtt with 15Q or mtHtt with 138Q, provided by L.M. Ellerby (Buck Institute for Age Research)). In a number of experiments, we concurrently transfected cells with EGFP to facilitate identification of transduced cells. We subsequently stained the labeled cells with antibody to NeuN (Millipore, MAB377) or MAP2 (Sigma, M9942) to verify their neuronal identity. In a series of experiments, we also transfected a PGC-1α expression vector (American Type Culture Collection). The transfection efficiency was 10-15% for cortical neurons and 5-10% for striatal neurons. In experiments manipulating synaptic activity, we added drugs (tetrodotoxin (Tocris), NO-711 (Sigma), memantine (Sigma), ifenprodil (Tocris) or CNQX (Sigma)) to cultures 5 h after transfection. We set extracellular Mg 2+ at ~0.4 mM to produce spontaneous NMDAR activity in the absence of excessive AMPAR stimulation, as assessed by patch-clamp recordings 42 . We analyzed CREB transcriptional activity with a CRE luciferase reporter (Stratagene) and Renilla luciferase internal control vector (Promega), as previously described 41 . We constructed siSTRIKE plasmids expressing shRNAs targeting TCP-1 and a nontargeted sequence according to the manufacturer's protocol (Promega). We designed the shRNAs targeting TCP-1 sequences with Promega's Target Designer (RNAi-1, 5′-GGCCACCAUUCUGAAAUUA-3′; RNAi-2, 5′-GCUGUGCUUGCUGUUAAAU-3′).
Assessment of inclusion formation and neuronal cell death.
For assessment of inclusions, we stained Htt-transfected cortical or striatal neurons with antibody to Myc (for truncated N-terminal Htt constructs, Santa Cruz (A-14)), or antibody to huntingtin (for full-length Htt constructs, Millipore (MAB2166 or MAB5374)) to visualize huntingtin expression under deconvolution microscopy. The expression of transfected full-length Htt was sufficiently above baseline to allow us to easily distinguish transfected from endogenous Htt ( Supplementary  Fig. 3) . We captured images with a Zeiss Axiovert 100M microscope equipped with deconvolution software (Supplementary Methods) .
In a series of experiments combining inclusion and neuronal cell death analysis, we transfected wtHtt or mtHtt either with a Myc tag or along with EGFP to facilitate identification of transduced cells; in this manner, we could normalize the number of viable, dead or inclusion-containing neurons to the total number of transfected neurons for each treatment paradigm (neurons identified by MAP2 and NeuN staining). We assessed inclusion formation 15-40 h and cell death 20-40 h after drug application. In the cell death experiments, we incubated wtHttor mtHtt-expressing neurons in DMEM/F12 medium (Invitrogen) for cortical neurons and Neurobasal Medium (Invitrogen) for striatal neurons with or without 50 µM glutamate for 40 h. In another series of experiments, we incubated cultures for 20 h with tetrodotoxin (Tocris) or NO-711 (Sigma). We then stained the cells with antibody to PGC-1α (Santa Cruz, H-300) or TCP-1 α (Santa Cruz, H-110) and Hoechst dye 33342. We assessed neuronal cell death on the basis of condensed nuclear morphology (with Hoechst dye) and shrunken neurites 30 . In the assessment of both inclusion formation and neuronal cell death, for each experimental condition, we counted ≥100 neurons on triplicate coverslips, and we repeated the experiments at least four times; thus, n ≥ 1200 in each case.
Electrophysiological recordings.
We made whole-cell recordings with an Axopatch 200B amplifier (Axon Instruments) from EGFP-positive neurons 48 to 96 h after transfection 42 . The extracellular solution contained 135 mM NaCl, 2.5 mM KCl, 2 mM CaCl 2 , 0-0.01 mM MgCl 2 , 1 mM NaHCO 3 , 0.34 mM Na 2 HPO 4 , 0.44 mM KH 2 PO 4 , 20 mM glucose and 10 mM HEPES, pH 7.4. We filled patch electrodes with a final tip resistance of 4-7 MΩ with a solution containing 120 mM CsCl, 20 mM tetraethylammonium chloride, 10 mM HEPES, 2.25 mM EGTA, 1 mM CaCl 2 , 2 mM MgCl 2 and 0.001 mM phalloidin, pH 7.4. To examine NMDAR-mediated sEPSCs, we used charge transfer. Details of this analysis are given in the Supplementary Methods and in Supplementary Figure 10 . We used pCLAMP 8-9.2 software (Axon Instruments) for data acquisition and analysis. Recordings were at 21 °C and a holding potential of −60 mV. We digitally sampled currents at 10-20 kHz and filtered them at 2-5 kHz.
Transgenic YAC128 mice. We used male and female YAC128 mice expressing expanded human huntingtin (HTT) with 128 CAG repeats and wild-type littermates maintained on the FVB/N strain (Charles River) for these experiments 8, 43 . We housed the mice singly or in pairs in duplex cages with littermates of mixed genotype and maintained them under a 12-h light and 12-h dark light cycle in a clean facility with free access to food and water. Experimenters were blind to the genotype of the mice. All whole-animal experiments were performed with the approval of the Animal Care Committee at the University of British Columbia.
Drug treatment. For administration of drugs in the drinking water, we monitored water consumption of individual cages on a biweekly-basis along with mouse body weights. We then adjusted the concentrations of drug solutions for each cage accordingly. We provided the solutions ad libitum and replaced them twice per week. We treated the mice starting at 2 months of age with 1 mg per kg body weight per day to 30 mg per kg body weight per day of memantine for 10 months, and we assessed their neuropathology and motor function at 12 months of age. We estimated the apparent effective concentration of memantine at the NMDAR-associated channel in vivo under these conditions after administration of low-dose memantine to be in the range of 5-10 µM on the basis of our current observations (see Supplementary Methods).
Assessment of motor function. We carried out training and baseline testing for motor function tasks before the initiation of memantine treatment at 2 months of age during the dark cycle. We carried out assessment of the effect of long-term (10-month) treatment with memantine on motor function by testing at 12 months of age. We assessed motor coordination and balance with accelerating and fixed-speed rotarod tasks (UGO Basile). In the accelerating task, the rotarod sped up from 5 r.p.m. to 40 r.p.m. over 4 min. In the fixed task, the rotarod revolved at 24 r.p.m. We assessed performance in the rotarod tasks by the amount of time that a mouse could remain running on the rotarod. During training, we gave mice three trials per day for 3 consecutive days.
Neuropathological analysis.
We stained a series of 25-µm-thick coronal sections spaced 200 µm apart spanning the striatum with NeuN-specific antibody (Millipore) overnight at 21 °C, followed by incubation with biotinylated mouse-specific antibody (Vector Laboratories). We amplified the signal with an ABC Elite kit (Vector) and detected it with diaminobenzidine (Pierce). We determined striatal volumes from a series of mounted sections using StereoInvestigator software (Microbrightfield) by tracing the perimeter of the striatum in serial sections spanning the striatum.
Assessment of huntingtin inclusions in vivo.
We immunoassayed perfused brain sections of 25 µm thickness from wild-type, untreated YAC128, or memantine-treated YAC128 mice with the antibody EM48 to assess the presence of mtHtt inclusions, as described previously 35 . We used polyclonal EM48 antibody at a 1:500 dilution with diaminobenzidine as the chromogen (Vector). We defined Htt inclusions as EM48-positive staining at the light microscope level. We took photographs of mounted sections on a light microscope (Zeiss) under a 100× objective using a MetaMorph Imaging System (Molecular Devices), and we measured the intensity of the staining of striatal neurons.
Statistical analysis. Data are expressed as means ± s.e.m. We interpreted the statistical significance of multiple comparisons by one-way ANOVA with a Student-Newman-Keuls post hoc test or Dunnett's post hoc test. We assessed pairwise comparisons between control and treatment groups with a Student's t test. Differences were considered statistically significant at P < 0.05. Methods. 
Additional methods. Additional methodology is provided in the Supplementary
